Tegaserod

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Irritable Bowel Syndrome With Constipation

Conditions

Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation

Trial Timeline

— → —

NCT ID

NCT00511771

About Tegaserod

Tegaserod is a pre-clinical stage product being developed by Novartis for Irritable Bowel Syndrome With Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT00511771. Target conditions include Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

20 competing products in Irritable Bowel Syndrome With Constipation

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	52
YM060 + Placebo	Astellas Pharma	Phase 3	77
Ramosetron + Placebo	Astellas Pharma	Approved	85
Ramosetron + Placebo	Astellas Pharma	Approved	85
YM060	Astellas Pharma	Phase 3	77
YM060 + placebo	Astellas Pharma	Phase 2	52
YM060	Astellas Pharma	Phase 3	77
linaclotide + Placebo	Astellas Pharma	Phase 3	77
Ramosetron	Astellas Pharma	Pre-clinical	23
YM060	Astellas Pharma	Phase 2	52
ONO-2952 + Placebo comparator	Ono Pharmaceutical	Phase 2	52
ONO-2952 + ONO-2952 Matching Placebo	Ono Pharmaceutical	Phase 2	52
duloxetine	Eli Lilly	Approved	85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)	AbbVie	Phase 3	77
25mg Eluxadoline + 100mg Eluxadoline	AbbVie	Phase 3	77
Eluxadoline + Placebo	AbbVie	Phase 2	52
Placebo + Linaclotide	AstraZeneca	Phase 3	77
DNK333	Novartis	Phase 2	52
SMS995 + Placebo	Novartis	Phase 1	33
DNK333 + Placebo	Novartis	Phase 2	52

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved